Get the Stockscreener App
0.8057
40.78%
0.2257
After Hours:
.79
-0.0157
-1.95%
X 4 Pharmaceuticals Inc stock is traded at $0.8057, with a volume of 7.71M.
It is up +40.78% in the last 24 hours and up +131.76% over the past month.
X4 Pharmaceuticals Inc is a late-stage clinical biopharmaceutical company engaged in the research and development of novel therapeutics for the treatment of rare diseases and those with limited treatment options, with a focus on conditions resulting from dysfunction of the immune system. The Company's lead clinical candidate is mavorixafor, a small molecule antagonist of the chemokine receptor CXCR4 that is being developed as an oral, once-daily therapy. It has the ability to increase the mobilization of mature, functional white blood cells from the bone marrow into the bloodstream. It also has two pre-clinical candidates X4P-003 and X4P-002 which are CXCR4 antagonists with different properties.
See More
Previous Close:
$0.58
Open:
$0.6015
24h Volume:
7.71M
Relative Volume:
2.42
Market Cap:
$124.81M
Revenue:
-
Net Income/Loss:
$-101.17M
P/E Ratio:
-0.7747
EPS:
-1.04
Net Cash Flow:
$-96.57M
1W Performance:
+34.45%
1M Performance:
+131.76%
6M Performance:
-18.35%
1Y Performance:
-3.10%
1-Day Range:
$0.60
$0.8423
1-Week Range:
$0.5293
$0.8423
52-Week Range:
$0.2612
$1.60
X 4 Pharmaceuticals Inc Stock (XFOR) Company Profile
Name
X 4 Pharmaceuticals Inc
Sector
Industry
Phone
857-529-8300
Address
61 NORTH BEACON STREET, BOSTON, MA
Compare XFOR with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
XFOR
X 4 Pharmaceuticals Inc
|
0.8057 | 124.81M | 0 | -101.17M | -96.57M | -0.59 |
|
VRTX
Vertex Pharmaceuticals Inc
|
410.65 | 105.21B | 10.63B | -479.80M | -1.35B | -1.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
716.68 | 78.48B | 13.85B | 4.65B | 3.32B | 40.41 |
|
ARGX
Argen X Se Adr
|
632.04 | 37.55B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
242.50 | 31.19B | 2.09B | -332.26M | 16.06M | -2.62 |
|
BNTX
Biontech Se Adr
|
113.77 | 27.43B | 3.30B | -501.07M | 1.03B | -2.1146 |
X 4 Pharmaceuticals Inc Stock (XFOR) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Dec-12-23 | Downgrade | B. Riley Securities | Buy → Neutral |
| Aug-30-23 | Resumed | B. Riley Securities | Buy |
| Dec-22-22 | Initiated | Cantor Fitzgerald | Overweight |
| Dec-12-22 | Initiated | Piper Sandler | Overweight |
| Dec-23-19 | Initiated | Oppenheimer | Outperform |
| Dec-18-19 | Initiated | ROTH Capital | Buy |
| Dec-09-19 | Upgrade | Citigroup | Neutral → Buy |
| Dec-05-19 | Initiated | B. Riley FBR | Buy |
| Jun-07-19 | Initiated | Stifel | Buy |
| Jun-05-19 | Initiated | Cowen | Outperform |
View All
X 4 Pharmaceuticals Inc Stock (XFOR) Latest News
How To Check Senores Pharmaceuticals IPO Allotment Status? Find Latest GMP, Listing Date And More - NDTV Profit
Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) Stock Rockets 27% As Investors Are Less Pessimistic Than Expected - Simply Wall St
Senores Pharmaceuticals IPO oversubscribed 93.69 times; check allotment and listing details - Zee Business
Senores Pharmaceuticals IPO Day 3 Highlights: Issue booked 93.41 times on third day; check GMP & other details | Stock Market News - Mint
Senores Pharmaceuticals IPO: Issue subscribed 93 times on last day; here’s how to check allotment status - Upstox
Layoff Tracker: Stubborn Layoff Trend Continues Across Biopharma in 2024 - BioSpace
5 Companies That Celebrated First Approvals in 2024 - BioSpace
XTX Topco Ltd Raises Holdings in X4 Pharmaceuticals, Inc. (NASDAQ:XFOR) - Defense World
Grace Therapeutics And 2 Other US Penny Stocks Worth Watching - Simply Wall St
Top 10 pharma companies in India by market cap [2024] - Forbes India
TRYNGOLZA™ (olezarsen) approved in U.S. as first-ever treatment for adults living with familial chylomicronemia syndrome as an adjunct to diet - Quantisnow
Top 10 Pharma Companies In India By Market Cap [2024] - Forbes India
Global Antibody Drug Conjugates Market Set For 23.4% Growth, Reaching $24.8 Billion By 2028 - EIN News
FDA Tracker: FDA Hands Out Atopic Dermatitis Approvals to Galderma, Organon - BioSpace
Verition Fund Management LLC Buys Shares of 44,355 X4 Pharmaceuticals, Inc. (NASDAQ:XFOR) - Defense World
Granules India gets USFDA nod for generic drug - The Economic Times
Granules India gets US regulator FDA's approval for generic ADHD drug - Business Standard
Global Pharmaceutical Cartridges Market Set For 9.9% Growth, Reaching $3.29 Billion By 2028 - EIN News
Pieris Pharmaceuticals Announces $5 Million Milestone from Seagen for Initiation of Phase 1 Trial of Cd228 X 4-1Bb Bispecific Molecule (Mabcalin Sgn-Bb228 (Prs-346) - Marketscreener.com
Global Nanopharmaceuticals Market Set For 17.0% Growth, Reaching $183.89 Billion By 2028 - EIN News
Companies partner to advance X-ray crystallography in early drug discovery - European Pharmaceutical Manufacturer
MIRA Pharmaceuticals Validates Ketamir-2's Safety Profile With No Adverse Findings, Paving the Way for IND Submission by Year-End - Eagle-Tribune
What is Duloxetine? Antidepressant Drug Recalled by FDA - Newsweek
OliX Pharmaceuticals, Inc (KOSDAQ:226950) Looks Just Right With A 34% Price Jump - Simply Wall St
Xenon Showcases New Long-Term Azetukalner Data from X-TOLE OLE Study in FOS at AES 2024 - The Manila Times
Universe Pharmaceuticals stock hits 52-week low at $1.66 - Investing.com
Phanes Therapeutics' PT217 granted Fast Track Designation by the FDA for NEPC - PR Newswire
X4 Pharmaceuticals to Present Trial-in-Progress Poster on Phase 3 Study of Mavorixafor in Chronic Neutropenia at 66th ASH Annual Meeting & Exposition - The Manila Times
Sony Group Corporation (NYSE:SONY): A Bullish Investment Perspective - Yahoo Finance
X4 Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewswire
Accord BioPharma Announces Agreement by Intas Pharmaceuticals, Ltd. to Acquire UDENYCA® (pegfilgrastim-cbqv) Business from Coherus BioSciences, Inc., Unlocking Potential for Continued U.S. Growth - BioSpace
2024's 10 Best-Performing Stocks | Investing - U.S News & World Report Money
Rigel Announces R289 Granted Fast Track Designation by the FDA for Lower-Risk MDS - PR Newswire
B.C. can sue opioid providers for health-care costs on behalf of other governments, Canada's top court rules - CBC News
Amylyx Pharmaceuticals to Present at the 7th Annual Evercore ISI HealthCONx Conference - Business Wire
SEC Form 4 filed by CEO, President Rodriguez Raul R - Quantisnow
X4 Pharmaceuticals to Participate in the 36th Annual Piper Sandler Healthcare Conference - The Manila Times
Poseida Therapeutics, Inc. Announces Agreement to be Acquired by Roche Holdings, Inc. - PR Newswire
ORIC® Pharmaceuticals to Participate in Upcoming Investor Conferences - The Manila Times
Two Smaller Companies Worthy of Your "Attention" - Yahoo Finance
Global X-ray Photoelectron Spectroscopy Market to Reach USD - GlobeNewswire
7 Companies Owned by Pfizer - Investopedia
x4 pharmaceuticals, inc. Earnings dates - RTTNews
Lexicon Pharmaceuticals to lay off 60% of workforce after FDA setback - Reuters.com
FDA approves cancer drug developed by B.C.'s Zymeworks - Business in Vancouver
Atenolol Global Market 2024 – Top Manufacturers, Latest Trends, Future Prospects And Outlook By 2033 - WhaTech
B. Riley Predicts Increased Earnings for X4 Pharmaceuticals - Defense World
Spotlight On 3 US Penny Stocks With At Least $60M Market Cap - Simply Wall St
B. Riley Expects Stronger Earnings for X4 Pharmaceuticals - MarketBeat
Benzodiazepine Drugs Market Overview: Industry Insights, Demand Trends, Competitive Landscape, and Key Inno... - WhaTech
X 4 Pharmaceuticals Inc Stock (XFOR) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.13%
2.19%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):